Mapping the EQ-5D index from the cystic fibrosis questionnaire-revised using multiple modelling approaches

Health and Quality of Life Outcomes

Amanda Copans²  Clara Mukuria³  Binny Pinder¹  Sarah Acaster¹ 

[1] Oxford Outcomes Ltd, an Icon plc Company, Seacourt Tower, West Way, Oxford OX2 0JJ, UK;Gilead Sciences Inc, 333 Lakeside Drive, Foster City 94404, CA, USA;ScHARR, University of Sheffield, Regent Court, 30 Regent Street, Sheffield S1 4DA, UK

关键词: Quality of life;    EQ-5D;    CFQ-R;    Health utilities;    Mapping;   

Others  :  1144120
DOI  :  10.1186/s12955-015-0224-6

 received in 2014-07-28, accepted in 2015-02-17,  发布年份 2015

【 摘 要 】

Background

This study was designed to develop a mapping algorithm to estimate EQ-5D utility values from Cystic Fibrosis Questionnaire-Revised (CFQ-R) data.

Methods

A cross-sectional survey of adults with cystic fibrosis (CF) was conducted in the UK. The survey consisted of the CFQ-R, the EQ-5D and a background questionnaire. Eight regression models, exploring item and domain level predictors, were evaluated using three different modelling approaches: ordinary least squares (OLS), Tobit, and a two-part model (TPM). Predictive performance in each model was assessed by intraclass correlations, information criteria (Bayesian information criteria and Alkaike information criteria), and root mean square error (RMSE).

Results

The survey was completed by 401 participants. For all modelling approaches the best performing item level model included all items, and the best performing domain level model included the CFQ-R Physical-, Role- and Emotional-functioning, Vitality, Eating Disturbances, Weight, and Digestive Symptoms domains and a selection of squared terms. Overall, the item level TPM, including age and gender covariates performed best within sample validation, but OLS and TPM domain models with squared terms performed best out-of-sample and are recommended for mapping purposes.

Conclusions

Domain and item level models using all three modelling approaches reached an acceptable degree of predictive performance with domain models performing well in out-of-sample validation. These mapping functions can be applied to CFQ-R datasets to estimate EQ-5D utility values for economic evaluations of interventions for patients with cystic fibrosis. Further research evaluating model performance in an independent sample is encouraged.

【 授权许可】

   
2015 Acaster et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Cohen-Cymberknoh M, Shoseyov D, Kerem E: Managing cystic fibrosis: Strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med 2011, 183:1463-71.
• [2]Royce FH, Carl JC: Health-related quality of life in cystic fibrosis. Curr Opin Pediatr 2011, 23:535-40.
• [3]Quittner AL: Measurement of quality of life in cystic fibrosis. Curr Opin Pulm Med 1998, 4:326-31.
• [4]Wahl AK, Rustoen T, Hanestad BR, Gjengedal E, Moum T: Living with cystic fibrosis: impact on global quality of life. Heart Lung 2005, 34:324-31.
• [5]Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat L: Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002, 121:64-72.
• [6]Quittner AL, Buu A, Messer MS, Modi AC, Watrous M: Development and validation of the cystic fibrosis questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 2005, 128:2347-54.
• [7]Quittner AL, Buu A, Watrous M, Davis MA: The cystic fibrosis questionnaire (CFQ): user’s manual. Cystic Fibrosis Foundation, Washington, DC; 2000.
• [8]Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC: Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006, 354:241-50.
• [9]Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, et al.: National hypertonic saline in cystic fibrosis (NHSCF) study group: a controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006, 354:229-40.
• [10]National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013. NICE. 2013. http://www.nice.org.uk/article/pmg9/resources/non-guidance-guide-to-the-methods-of-technology-appraisal-2013-pdf.
• [11]Sauerland S, Weiner S, Dolezalova K, Angrisani L, Noguera CM, Garcia-Caballero M, et al.: Mapping utility scores form a disease-specific quality of life measure in bariatric surgery patients. Value Health 2009, 12:364-70.
• [12]Franks P, Lubetkin EI, Gold MR, Tancredi DJ, Jia H: Mapping the SF-12 to the EuroQol EQ-5D index in a national US sample. Med Decis Making 2004, 24:247-54.
• [13]Ara R, Brazier J: Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference –based score from published studies (where patient level data are not available). Value Health 2008, 11:1131-43.
• [14]Longworth L, Rowen D: Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health 2013, 16:202-10.
• [15]Brazier JR, Yang Y, Tsuchiya A, Rowen DL: A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ 2010, 11:215-25.
• [16]Rabin R, de Charro F: EQ-D5: a measure of health status from the EuroQol group. Ann Med 2001, 33:337-43.
• [17]Brooks R: EuroQol: the current state of play. Health Policy 1996, 37:53-72.
• [18]Group EQ: EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990, 16:199-208.
• [19]Dolan P: Modeling valuations for EuroQol health states. Med Care 1997, 35:1095-8.
• [20]Chuang L-H, Whitehead SJ: Mapping for economic evaluation. Br Med Bull 2012, 101:1-15.
• [21]Dakin H, Petrou S, Haggard M, Benge S, Williamson I: Mapping analyses to estimate health utilities based on responses to the OM8-30 Otitis Media Questionnaire. Qual Life Res 2010, 19:65-80.
• [22]Chuang L-H, Kind P: Converting the SF-12 into the EQ-5D: an empirical comparison of methodologies. Pharmacoeconomics 2009, 27:491-505.
• [23]Huang IC, Frangakis C, Atkinson MJ, Willke RJ, Leite WL, Vogel WB, et al.: Addressing ceiling effects in health status measures: a comparison of techniques applied to measures for people with HIV disease. Health Serv Res 2008, 43:327-39.
• [24]Quittner AL, Sawicki GS, McMullen A, Rasouliyan L, Pasta DJ, Yegin A, et al.: Psychometric evaluation of the cystic fibrosis questionnaire-revised in a national, US sample. Qual Life Res 2012, 21:1279-90.
• [25]Bradley JM, Blume SW, Balp M-M, Honeybourne D, Elborn JS: Quality of life and healthcare utilisation in cystic fibrosis: a multicentre study. Eur Respir J 2013, 41:571-7.
• [26]Versteegh M, Rowan DL, Brazier JE, Stolk EA: Mapping onto EQ-5D for patients for patients in poor health. Health Qual Life Outcomes 2010, 8:141. BioMed Central Full Text
• [27]Rowan DL, Brazier JE, Roberts J: Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? Health Qual Life Outcomes 2009, 7:27. BioMed Central Full Text
• [28]Sanders DB, Bittner RCL, Rosenfeld M, Redding GJ, Goss CH: Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011, 46:393-400.
• [29]Jarad NA, Higgs S, Jeffcote T, Giles K: Factors associated with reduced FEV1 in adult patients with cystic fibrosis in a relatively affluent area. Chron Respir Dis 2005, 2:133-7.